SRR1498616
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.360
- INTERFERON_ALPHA_RESPONSE+0.340
- INFLAMMATORY_RESPONSE+0.284
- APICAL_JUNCTION+0.242
- PANCREAS_BETA_CELLS+0.236
- INTERFERON_GAMMA_RESPONSE+0.234
- COMPLEMENT+0.217
- CHOLESTEROL_HOMEOSTASIS+0.212
- KRAS_SIGNALING_UP+0.197
- ESTROGEN_RESPONSE_LATE+0.181
Top 10 suppressed
- MYC_TARGETS_V1-0.543
- MYC_TARGETS_V2-0.540
- E2F_TARGETS-0.526
- G2M_CHECKPOINT-0.479
- DNA_REPAIR-0.475
- OXIDATIVE_PHOSPHORYLATION-0.449
- UNFOLDED_PROTEIN_RESPONSE-0.436
- MTORC1_SIGNALING-0.259
- ADIPOGENESIS-0.232
- PI3K_AKT_MTOR_SIGNALING-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Y7F9E2E9 | low-grade glioma | — | 0.908 |
| 2 | SRR598671 | GTEX | — | 0.904 |
| 3 | s_150324_2b | EPN | Posterior Fossa EPN | 0.902 |
| 4 | SRR1338627 | GTEX | — | 0.892 |
| 5 | SRR1312743 | GTEX | — | 0.887 |
| 6 | SRR1500639 | GTEX | — | 0.886 |
| 7 | SRR608230 | GTEX | — | 0.883 |
| 8 | ERR2208964 | — | — | 0.880 |
| 9 | SRR601006 | GTEX | — | 0.879 |
| 10 | BS_5PEFNDCY | Glial-neuronal tumor NOS | — | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.284 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.242 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.236 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.234 | Idelalisib | — uncovered |
| COMPLEMENT | 0.217 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.212 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.197 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.181 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.163 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.158 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.148 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.099 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.096 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.096 | Inavolisib | — uncovered |
| COAGULATION | 0.086 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.070 | Idelalisib | — uncovered |